Showing results (241-250 of 296) with videos related to

Sort By:
Pageof 30
Blood|February 1, 1997
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myelomaB Barlogie, S Jagannath, D H Vesole, et al.
Nature Genetics|December 28, 1999
Leukaemia disease genes: large-scale cloning and pathway predictionsJ Li, H Shen, K L Himmel, et al.
Bone Marrow Transplantation|January 26, 2006
Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantationC-K Lee, M Zangari, A Fassas, et al.
Leukemia|April 25, 2008
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myelomaM Pineda-Roman, M Zangari, F van Rhee, et al.
The New England Journal of Medicine|November 24, 1999
Antitumor activity of thalidomide in refractory multiple myelomaS Singhal, J Mehta, R Desikan, et al.
Bone Marrow Transplantation|October 6, 1997
Feasibility and cost-effectiveness of outpatient autotransplants in multiple myelomaS Jagannath, D H Vesole, M Zhang, et al.
Blood|May 23, 1998
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantationC S Zent, C S Wilson, G Tricot, et al.
Bone Marrow Transplantation|February 10, 2004
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplantC-K Lee, M Zangari, B Barlogie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity studyG Tricot, D S Alberts, C Johnson, et al.
Investigational New Drugs|May 1, 1993
Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group studyM E Marshall, M K Wolf, E D Crawford, et al.
Pageof 30